Fig. 4

Differential diagnostic efficiency of serum SV2A combined with other biomarkers in AD vs. VaD and AD vs. PDD. a–c. Differential diagnostic efficiency of serum NfL, GFAP, and p-tau217 in AD vs. VaD. d–g. Differential diagnostic efficiency of serum SV2A + NfL, SV2A + GFAP, SV2A + p-tau217, and SV2A + NfL + GFAP + p-tau217 in AD vs. VaD. h–j. Differential diagnostic efficiency of serum NfL, GFAP, and p-tau217 in AD vs. PDD. k–n. Differential diagnostic efficiency of serum SV2A + NfL, SV2A + GFAP, SV2A + p-tau217, and SV2A + NfL + GFAP + p-tau217 in AD vs. PDD. Abbreviations: 95% CI, 95% confidence interval; AD, Alzheimer’s disease; AUC, area under the curve; PDD, Parkinson’s disease dementia; SV2A, synaptic vesicle glycoprotein 2 A; VaD, vascular dementia; vs., versus